Description
Key facts
Cell type:THP-1,
Species or organism:Human,
Tissue:Blood,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 1,
Disease:Acute Monocytic Leukemia
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
Treatments:
Human CCL4 knockout THP-1 cell lysate - Brefeldin A (5 μg/ml, 6h)
Human wild-type THP-1 cell lysate - Brefeldin A (5 μg/ml, 6h)
Human CCL4 knockout THP-1 cell lysate - PMA (100 ng/ml, 56h), LPS (1 μg/ml, 24h) and Brefeldin A (5 μg/ml, during the last 6h of LPS treatment)
Human wild-type THP-1 cell lysate - PMA (100 ng/ml, 56h), LPS (1 μg/ml, 24h) and Brefeldin A (5 μg/ml, during the last 6h of LPS treatment)
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
Properties and Storage Information:
Gene name-CCL4L1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CCL4 also known as MIP-1 beta or MIP-1b has a mechanical role as a chemokine involved in immune response regulation. The protein has a mass of about 7.8 kDa. It expresses in various tissues including leukocytes where it mainly functions as a chemoattractant. MIP-1 beta helps recruit immune cells like natural killer cells and monocytes to sites of inflammation or injury. Researchers frequently measure its levels using assays like MIP-1 beta ELISA or CCL4 ELISA.
Biological function summary
CCL4 is critical in immune system modulation. It coordinates leukocyte activation and trafficking contributing to inflammation and immune surveillance. It does not function in isolation but rather interacts with other chemokines and receptors. CCL4 alongside its sibling chemokines forms a dynamic network that ensures a balanced immune response. It connects to receptors such as CCR5 playing substantial roles in its activities.
Pathways
CCL4 participates in essential signaling cascades that mediate immune responses. It is notably part of the chemokine signaling pathway which is instrumental in directing cell movement. CCL4 also engages with proteins like CCR5 in the inflammatory and immune response pathways. This interaction enhances communication between cells required for effective pathogen defense.
CCL4 plays roles in immune-related conditions. It is strongly linked to inflammatory diseases such as rheumatoid arthritis and HIV infection. In rheumatoid arthritis CCL4 levels are often elevated correlating with inflammation severity. During HIV infection CCL4 interacts with proteins like CCR5 a co-receptor the virus uses to enter host cells. This involvement makes MIP-1 beta a target for studies seeking therapeutic interventions in these diseases.
